Article Details

Avidity Biosciences (NASDAQ:RNA) Upgraded by Zacks Investment Research to “Hold”

Retrieved on: 2022-04-16 11:41:39

Tags for this article:

Click the tags to see associated articles and topics

Avidity Biosciences (NASDAQ:RNA) Upgraded by Zacks Investment Research to “Hold”. View article details on hiswai:

Excerpt

The biotechnology company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.09). Avidity Biosciences had a ...

Article found on: finnewslive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up